CLSD

Clearside Biomedical Inc

CLSD.US clearsidebio.com + Research + Basket
CIK 0001539029
Employees 32
Phone 678 270 3631
Fiscal year end December
IPO Jun 02, 2016
Address 900 North Point Parkway, Alpharetta, GA, United States, 30005
Price N/A
USD · NASDAQ
52-week range
0.39
4.26
Market Cap
2.15M
P/E Ratio
0.00
Forward P/E
0.00
Book Value
-10.31
Div. Yield
N/A
% Institutions
13.68%
% Insiders
12.88%

1 Year

-97.4%

3 Year

-97.6%

10 Year

-99.6%
Description

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD. The company has a collaboration with bausch + lomb ireland limited, Arctic Vision (Hong Kong) Limited, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences, Inc. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia. On November 23, 2025, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Actions

Add an action for CLSD.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D. Director & Principal Executive Officer 1952
Mr. Charles A. Deignan Principal Financial Officer & Principal Accounting Officer 1964
Ms. Jenny R. Kobin Head of Investor Relations 1967
Mr. Rick McElheny Senior Vice President of Corporate Development & Alliance Management NA
Mr. Rafael V. Andino Senior Vice President of Engineering & Manufacturing 1965

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Feb 24, 2025 Clay Thorp N/A Purchase 1.00K $13.80 $13.80K SEC
Nov 01, 2024 Ngai Hang Victor Chong N/A Purchase 2.43K $15.00 $36.50K SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Vanguard Group Inc 3.36M Jun 30, 2025 0.29% $0.00 19.83%
Carmignac Gestion 1.51M Jun 30, 2025 0.13% $0.02 0.00%
Geode Capital Management, LLC 790.37K Jun 30, 2025 0.07% $0.00 -0.24%
BlackRock Inc 625.19K Jun 30, 2025 0.05% $0.00 -21.94%
GSA Capital Partners LLP 533.52K Jun 30, 2025 0.05% $0.03 164.66%
Renaissance Technologies Corp 496.59K Jun 30, 2025 0.04% $0.00 -10.45%
First Manhattan Co. LLC 342.73K Jun 30, 2025 0.03% $0.00 0.00%
State Street Corp 265.26K Jun 30, 2025 0.02% $0.00 0.00%
Bridgeway Capital Management, LLC 205.00K Jun 30, 2025 0.02% $0.00 -19.61%
Northern Trust Corp 165.50K Jun 30, 2025 0.01% $0.00 0.00%
Assenagon Asset Management SA 131.91K Jun 30, 2025 0.01% $0.00 0.00%
Morgan Stanley - Brokerage Accounts 130.90K Jun 30, 2025 0.01% $0.00 0.00%
PNC Financial Services Group Inc 107.92K Jun 30, 2025 0.01% $0.00 0.00%
Brown Wealth Management, LLC 100.00K Jun 30, 2025 0.01% $0.02 0.00%
Northeast Financial Consultants, Inc 93.00K Jun 30, 2025 0.01% $0.00 0.00%
Susquehanna International Group, LLP 89.62K Jun 30, 2025 0.01% $0.00 170.19%
CapTrust Financial Advisors 87.00K Jun 30, 2025 0.01% $0.00 0.00%
Stifel Financial Corp 39.94K Jun 30, 2025 0.00% $0.00 66.82%
Investor's Fiduciary Advisor Network, LLC 33.80K Jun 30, 2025 0.00% $0.01 0.00%
UBS Group AG 32.51K Jun 30, 2025 0.00% $0.00 -47.62%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Total Stock Mkt Idx Inv 1.93M 0.16% ▼ 2.14% Jul 31, 2025
2 Carmignac Pf L-S Eurp Eqs F EUR Acc 1.51M 0.13% ▲ 0.00% Jun 30, 2025
3 Vanguard Institutional Extnd Mkt Idx Tr 880.90K 0.07% ▼ 31.30% Jul 31, 2025
4 Fidelity Extended Market Index 375.52K 0.03% ▼ 0.82% Jul 31, 2025
5 Bridgeway Ultra-Small Company Market 205.00K 0.02% ▼ 19.61% Jun 30, 2025
6 Fidelity Total Market Index 139.26K 0.01% ▼ 0.21% Jul 31, 2025
7 Extended Equity Market Fund K 122.83K 0.01% ▼ 1.96% Jun 30, 2025
8 Fidelity Series Total Market Index 96.43K 0.01% ▲ 0.00% Jul 31, 2025
9 NT Ext Equity Mkt Idx Fd - L 90.40K 0.01% ▲ 0.00% Jun 30, 2025
10 Northern Trust Extended Eq Market Idx 90.40K 0.01% ▲ 0.00% Jun 30, 2025

Financial Highlights

▼
Market Cap: $2.15M
EBITDA: $-22.63M
PEG Ratio: $0.00
Book Value: $-10.31
Earnings/Share: $-5.11
Profit Margin: 0.00%
Operating Margin: -3,502.49%
ROA (TTM): -70.35%
ROE (TTM): -1,310.02%
Revenue (TTM): $3.33M
Revenue/Share (TTM): $0.65
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -80.60%

Valuation Metrics

Enterprise Value: $-2.43M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 5.23M
Shares Float: 4.54M
% Insiders: 12.88%
% Institutions: 13.68%
Short % Float: 2.74%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$1.66M
Cost of Goods Sold
adjust
$-149.00K
Gross Profit
subtotal
$1.52M
SG&A
adjust
$-11.81M
R&D
adjust
$-18.59M
Operating Income
subtotal
$-28.88M
Other / Non-Operating Items
adjust
$-5.47M
Net Income
subtotal
$-34.35M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about CLSD.US!